BACKGROUND: Linear scleroderma and Parry-Romberg Syndrome (PRS) are chronic diseases that can affect the face, with patients therefore requiring facial volumetric correction. OBJECTIVE: We have used poly-L-lactic acid (PLLA) to treat facial asymmetry in patients with linear scleroderma and PRS, because it can restore volumetric defects and has been proven to be safe. MATERIALS AND METHODS: Since February 2004, we have treated six patients: four with linear scleroderma and two with PRS. The patients were treated every 4 weeks for three to five sessions. Photographic documentation was taken at the beginning and at the completion of every treatment and 12 and 18 months later. RESULTS: In patients with PRS and linear scleroderma of the face, we noticed good restoration of facial volume and symmetry and improvement in skin quality. The results were found to be permanent at 18 months in patients with PRS and 12 months in patients with linear scleroderma. CONCLUSIONS: PLLA has been shown to be a useful material for the correction of small volumetric defects caused by linear scleroderma and PRS. The authors have indicated no significant interest with commercial supporters.
BACKGROUND:Linear scleroderma and Parry-Romberg Syndrome (PRS) are chronic diseases that can affect the face, with patients therefore requiring facial volumetric correction. OBJECTIVE: We have used poly-L-lactic acid (PLLA) to treat facial asymmetry in patients with linear scleroderma and PRS, because it can restore volumetric defects and has been proven to be safe. MATERIALS AND METHODS: Since February 2004, we have treated six patients: four with linear scleroderma and two with PRS. The patients were treated every 4 weeks for three to five sessions. Photographic documentation was taken at the beginning and at the completion of every treatment and 12 and 18 months later. RESULTS: In patients with PRS and linear scleroderma of the face, we noticed good restoration of facial volume and symmetry and improvement in skin quality. The results were found to be permanent at 18 months in patients with PRS and 12 months in patients with linear scleroderma. CONCLUSIONS: PLLA has been shown to be a useful material for the correction of small volumetric defects caused by linear scleroderma and PRS. The authors have indicated no significant interest with commercial supporters.